Vodis Pharmaceuticals Inc. (CSE: VP / FSE: 1JV1) announces that it has extended the financing with Canaccord Capital (previously announced June 20 th , 2017) to September 30, 2017 (the “Offering”).

The Company anticipates closing its initial tranche of the Offering in the near term.


Ivan Miliovski, Vodis’ CEO states, “We remain engaged with Canaccord and are working with their team to raise the necessary capital to execute on the remainder of our 2017 business initiatives.  The delay in closing has been caused by due diligence taking longer than expected and anticipate we can look to close on additional funds as summer comes to an end.  The entire sector has witnessed a correction in valuations – increasing the duration of thorough due diligence.  However, Vodis remains well positioned with an extremely attractive capital structure.”

In addition, the Company is very pleased to announce the appointment of Dr. Earl Oliver to direct and control the Company’s application with Health Canada.  Dr. Oliver is a technology entrepreneur and activist investor.  He holds a B.Math and Ph.D. in Computer Science from the University of Waterloo and is a large investor in Vodis.

Dr. Oliver states, “The company has been, justifiably, focused on expanding its brand and turn-key model in the lucrative Washington State, and broader American, recreational market.  However, as Canada transitions towards a recreational market, it is apparent that the Company’s application with Health Canada requires full-time attention.  I look forward to guiding the Company through a successful application process.  Progress updates will be forthcoming.”

Vodis USA’s Washington State tenant has informed the Company that they changed their name from Our Church International LLC to Premium Cannabis Producers LLC (the “Tenant”).  Under the terms of the licensing deal announced February 23, 2017, all product sold by the Tenant are sold under the Vodis USA brand.

The Tenant also reported an outbreak of powder mildew that affected production and sales late June and into July. Proper measures were taken to correct the deficiency and there is now no evidence of contamination present on site.  The Tenant has also confirmed that all lots harvested in the month of August have successful passed microbiological, as well as all other quality assurance testing requirements, by the Washington State Liquor & Cannabis Board.

This press release shall not constitute an offer to sell or solicitation of an offer to buy the securities in any jurisdiction. The securities will not be and have not been registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or applicable exemption from the registration requirements.

About Vodis Pharmaceuticals Inc.

Vodis is one of North America’s foremost brand names in the medical and recreational marijuana business with operations in both the United States and Canada.  Its master grow teams have consistently won or placed at each Canadian competition they have entered with their “VIP” brand.  The Company, with facilities in British Columbia and Washington State, is also actively looking into expansion opportunities in other countries and throughout the United States.

For further information, please contact:

Ivan Miliovski, CEO

Vodis Pharmaceuticals Inc.

1-866-210-1420 Ext103

 -or-

Soy Garipoglu

Investor Relations

Vodis Pharmaceuticals Inc.

8788 River Road

Delta, BC V4G 1B4

Contact: 778-990-8985

Email: investorrelations@vodis.ca

Web: www.vodis.ca

Forward-Looking Information : This press release contains certain forward-looking information that reflects the current views and/or expectations of the Company with respect to its performance, business and future events, including statements regarding the Company’s expectations regarding completion of the Offering.  Forward-looking information is based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the business and the industry and markets in which the Company operates, including that the Company will receive subscriptions from subscribers and any required regulatory approvals in order to complete the Offering, and the Company will be able to satisfy the conditions for completing the Offering.  Statements constituting forward-looking information are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict.  Investors are cautioned that all forward-looking information involves risks and uncertainties, including that the Company will not receive subscriptions from subscribers or all required regulatory approvals in order to complete the Offering, that the conditions to completing the Offering will not be satisfied in a timely manner or at all,  and other risks and uncertainties listed in the Company’s public filings.  These risks, as well as others, could cause actual results and events to vary significantly.  Accordingly, readers should not place undue reliance on forward-looking information, which is qualified in their entirety by this cautionary statement.  There can be no assurance that forward-looking information, or the material factors or assumptions used to develop such forward-looking information, will prove to be accurate.  The Company does not undertake any obligations to release publicly any revisions for updating any voluntary forward-looking information, except as required by applicable securities law.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

Click here to connect with Vodis Pharmaceuticals Inc. (CSE:VP,FSE:1JV1) to receive an Investor Presentation.

Source: www.stockhouse.com

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Trading resumes in:

Company: 4Front Ventures Corp.

Keep reading... Show less

/NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES /

  4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) is pleased to announce that it has completed its previously announced bought deal prospectus offering (the ” Offering “) of units of the Company (” Units “), for aggregate gross proceeds of C$17,251,150 including full exercise of the over-allotment option granted to the underwriters in connection therewith.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff

Tactile Systems Technology (NASDAQ:TCMD)
Class Period:
May 7, 2018 – June 8, 2020
Deadline: November 30, 2020
For more info: www.bgandg.com/tcmd

Keep reading... Show less

Khiron Life Sciences Corp. (“ Khiron ” or, the “ Company ”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), announced today that it has re-filed its unaudited condensed interim consolidated financial statements, together with the notes thereto, for the three and six months ended June 30, 2020 and 2019 (the “ Interim Financial Statements ”) to correct, among other things, certain 2019 comparative period information and to update certain presentation arising from the Company’s early adoption of IFRS 3 in late 2019, which changes were identified in connection with the Company’s review engagement with its auditor. The Company does not consider these adjustments either individually nor in the aggregate, to be material.

The re-filed Interim Financial Statements reflect changes to the Condensed Interim Consolidated Statements of Loss and Comprehensive Loss comparative period to remove transaction fees from the income statement and capitalize them to the applicable acquisition in accordance with the Company’s early adoption of the amended IFRS 3 as set out in Note 2, and to reclassify $1 million from general and administrative expenses to transaction fees for presentation purposes to conform with the Company’s presentation used in its audited consolidated financial statements for the years ended December 31, 2019 and 2018 (the “ Audited Annual Financial Statements ”). The re-filed interim Financial Statements also reflect changes to the Condensed Interim Consolidated Statement of Changes in Shareholders’ Equity to correct the 2019 comparative period balances as they incorrectly reflect Q1 2019 period balances, update certain presentation to conform with the Company’s presentation used in its Audited Annual Financial Statements; and reduce the valuation conclusion of the Company’s acquisition of NettaGrowth International Inc. to conform with the Audited Annual Financial Statements. The re-filed Interim Financial Statements also bring forward the subsequent event note disclosure.

Keep reading... Show less